The Director of the Administrative/Clinical Service Core (ACSC) will be Dr. Susan Chang. The ACSC will have 2 components, Administrative (led by Dr. Chang) and Clinical (led by Dr. Clarke). In addition. Dr. Sarah Nelson and Dr. Mitchel Berger will serve as co-investigators of the core to provide oversight of the projects planned. Dr. Chang is the Director of the Division of Neuro-Oncology and is the co-director of the administrative core of the prior PPG. She is experienced in the coordination of multiple projects and cores and has effectively provided the leadership for the successful activities of the previous cycle. She has demonstrated clear commitment to providing oversight of the PPG.
The specific aims of the ACSC are to provide Administrative and Clinical services to all 3 Projects to accomplish their Specific Aims and Research Plans. Administrative support will include fiscal, grants management and clerical support for annual progress reports and manuscript preparation, and organization for meetings between the Individual Projects key personnel, as well as for meetings with the External Advisory Board. All 3 Projects will involve patient research studies and the clinical component will provide the infrastructure and personnel to allow the conduct of non-therapeutic and therapeutic research studies. This will include clinical scientists, neurosurgeons, research nurses and clinical research assistants, as well as clinical space to obtain informed consent, treat, and follow patients enrolled in clinical studies within all the Projects. The overall goal of the ACSC will be to facilitate the interactions of the members of this PPG, provide clinical research support for each of the Projects, and administratively coordinate activities of the PPG membership. The following table depicts the distribution of effort provided to the 3 Projects by the 2 components of the ACSC. Component Project 1 Project 2 Project 3 Total Administrative 33.3% 33.3% 33.3% 100% Clinical 50% 20% 30% 100%

Public Health Relevance

This PPG consists of 3 highly integrated projects focused on determining the role of imaging and tissue correlates in the optimization of care for patients with glioblastoma (GBM). Each project will study patients with GBM and the ACSC will facilitate the successful completion of the research aims by providing administrative and clinical support.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-2 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Lupo, Janine M; Molinaro, Annette M; Essock-Burns, Emma et al. (2016) The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro Oncol 18:87-95
Mazor, Tali; Pankov, Aleksandr; Song, Jun S et al. (2016) Intratumoral Heterogeneity of the Epigenome. Cancer Cell 29:440-51
Park, Ilwoo; von Morze, Cornelius; Lupo, Janine M et al. (2016) Investigating tumor perfusion by hyperpolarized (13) C MRI with comparison to conventional gadolinium contrast-enhanced MRI and pathology in orthotopic human GBM xenografts. Magn Reson Med :
Johannessen, Tor-Christian Aase; Mukherjee, Joydeep; Viswanath, Pavithra et al. (2016) Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res 14:976-983
Cao, Peng; Shin, Peter J; Park, Ilwoo et al. (2016) Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing. Magn Reson Med 76:369-79
Larson, Peder E Z; Han, Misung; Krug, Roland et al. (2016) Ultrashort echo time and zero echo time MRI at 7T. MAGMA 29:359-70
Radoul, Marina; Chaumeil, Myriam M; Eriksson, Pia et al. (2016) MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. Mol Cancer Ther 15:1113-22
Bell, Robert J A; Rube, H Tomas; Xavier-Magalhães, Ana et al. (2016) Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res 14:315-23
Nelson, Sarah J; Li, Yan; Lupo, Janine M et al. (2016) Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. J Neurooncol 130:171-179
Cao, Peng; Zhang, Xiaoliang; Park, Ilwoo et al. (2015) (1) H-(13) C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI. Magn Reson Med :

Showing the most recent 10 out of 51 publications